
|Videos|December 23, 2020
R/R Multiple Myeloma: Review of the CARTITUDE Trial
Author(s)Targeted Oncology
Recent updates from the ASH 2020 annual meeting on the phase 1b/2 CARTITUDE-1 trial for relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
3
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
4
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
5

















